Garankina R.Y.
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Garankina R.Y. has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- E. R. Zakharochkina
Sechenov First Moscow State Medical University (Sechenov University)
4 shared publications - A. V. Alekhin
Limited Liability Company “UK Pharmaclone Group”. 2. Bauman Moscow State Technical University
3 shared publications - Elena A. Maksimkina
Sechenov First Moscow State Medical University (Sechenov University)
3 shared publications - K. A. Chizhov
Sechenov First Moscow State Medical University (Sechenov University)
3 shared publications - Samoshchenkova I. F.
Orel State University named after I.S. Turgenev
3 shared publications - V. S. Fisenko
Ministry of Health of the Russian Federation
3 shared publications
Latest Publications
- Open Access
- 2 August 2025
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 13 (3) , 242
CORRIGENDUM: Regulation in the sphere of circulation of extemporaneously compounded medicines under modern conditions of Russia [. Pharmacy & Pharmacology. 2024;12(5):324-337. DOI: 10.19163/10.19163/2307-9266-2024-12-5-324-337]
Referred to by: Ryazhenov V.V., Maksimkina E.A., Fisenko V.S., Alekhin A.V., Tarasov V.V., Raisyan M.G., Zakharochkina E.R., Chizhov K.A., Garankina R.Yu. Regulation in the sphere of circulation of extemporaneously compounded medicines under modern conditions of Russia. Pharmacy & Pharmacology. 2024;12(5):324-337. https://doi.org/10.19163/2307-9266-2024-12-5-324-337 We hereby inform readers that in the final version of the article changes were made in Russian and English.In the published article " Regulation in the sphere of circulation of extemporaneously compounded medicines under modern conditions of Russia", the authors found an error: accidentally, due to a technical error on part and without any malicious intent, еhe regulatory document was incorrectly specified in table 1 (p.330):Resolution of the Government of the Russian Federation No. 546 “On Approval of the Regulations on Licensing of Pharmaceutical Activities” dated March 31, 2022.The authors regret that, due to an oversight, the cited regulatory document was incorrectly numbered (No. 546) in the originally published version of this article.Correct version:Resolution of the Government of the Russian Federation No. 547 “On Approval of the Regulations on Licensing of Pharmaceutical Activities” dated March 31, 2022. The error occurred due to the fault of the entire team of authors, but does not change the essence of the data presented in the article, does not violate their perception by readers or interpretation.The authors would like to apologize for any inconvenience. The authors declare no conflict of interest.The original article has been updated in online-version: https://www.pharmpharm.ru/jour/article/view/1664
- 2 August 2025
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 13 (3) , 242
Open AccessCORRIGENDUM: Regulation in the sphere of circulation of extemporaneously compounded medicines under modern conditions of Russia [. Pharmacy & Pharmacology. 2024;12(5):324-337. DOI: 10.19163/10.19163/2307-9266-2024-12-5-324-337]
Referred to by: Ryazhenov V.V., Maksimkina E.A., Fisenko V.S., Alekhin A.V., Tarasov V.V., Raisyan M.G., Zakharochkina E.R., Chizhov K.A., Garankina R.Yu. Regulation in the sphere of circulation of extemporaneously compounded medicines under modern conditions of Russia. Pharmacy & Pharmacology. 2024;12(5):324-337. https://doi.org/10.19163/2307-9266-2024-12-5-324-337 We hereby inform readers that in the final version of the article changes were made in Russian and English.In the published article " Regulation in the sphere of circulation of extemporaneously compounded medicines under modern conditions of Russia", the authors found an error: accidentally, due to a technical error on part and without any malicious intent, еhe regulatory document was incorrectly specified in table 1 (p.330):Resolution of the Government of the Russian Federation No. 546 “On Approval of the Regulations on Licensing of Pharmaceutical Activities” dated March 31, 2022.The authors regret that, due to an oversight, the cited regulatory document was incorrectly numbered (No. 546) in the originally published version of this article.Correct version:Resolution of the Government of the Russian Federation No. 547 “On Approval of the Regulations on Licensing of Pharmaceutical Activities” dated March 31, 2022. The error occurred due to the fault of the entire team of authors, but does not change the essence of the data presented in the article, does not violate their perception by readers or interpretation.The authors would like to apologize for any inconvenience. The authors declare no conflict of interest.The original article has been updated in online-version: https://www.pharmpharm.ru/jour/article/view/1664
- Open Access
- 23 July 2025
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 13 (2) , 128-138
Problems and Solutions of Pharmaceutical Packaging in Bulk
To date, pharmaceutical activities in the manufacture of medicines in a pharmacy, intra-pharmacy packaging of registered medicines in Russia and the countries of the Eurasian Economic Union (EAEU), is one of the priorities of regulatory authorities in order to improve drug supply.The aim. To study the current state of legal regulation of the circulation of medicines “in bulk” and the possibility of their packaging in a pharmacy.Materials and methods. To solve the tasks set, the methodology of system analysis in the field of drug provision, content analysis of documents regulating the sphere of circulation of drugs was used. The regulatory framework of the study was the legislative and by-laws regulating the sphere of circulation of medicines of the Russian Federation and the common market of the EAEU. The search for regulatory legal acts was carried out in the Directory of the legal system “ConsultantPlus”. In the course of the research, a set of scientific methods was used such a systematic, logical, structural and comparative.Results. The article consider the issues of legal regulation of the circulation of medicines “in bulk” in the pharmaceutical market. The current state of the legislative and regulatory framework has been studied and the problems of legal regulation of packaging of medicicnes “in bulk” in pharmacies have been identified. The article also focuses on the general problem of compliance with modern packaging requirements for medicines compounded in pharmacy. The possibility of introducing a new concept of “Pharmacy packaging” into Federal Law No. 61-FZ dated April 12, 2010 “On the circulation of medicines” is considered. The approaches developed in world practice to the regulation of issues related to the packaging of drugs “in bulk” in pharmacy are considered. Based on the results of the study, the possibilities have been identified and ways to improve the mechanisms of state regulation have been proposed.Conclusion. Packaging of medicines “in bulk” will increase the effectiveness of individual drug therapy, optimize and reduce the cost of circulation of budget funds, pharmacies and citizens.
- 23 July 2025
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 13 (2) , 128-138
Open AccessProblems and Solutions of Pharmaceutical Packaging in Bulk
To date, pharmaceutical activities in the manufacture of medicines in a pharmacy, intra-pharmacy packaging of registered medicines in Russia and the countries of the Eurasian Economic Union (EAEU), is one of the priorities of regulatory authorities in order to improve drug supply.The aim. To study the current state of legal regulation of the circulation of medicines “in bulk” and the possibility of their packaging in a pharmacy.Materials and methods. To solve the tasks set, the methodology of system analysis in the field of drug provision, content analysis of documents regulating the sphere of circulation of drugs was used. The regulatory framework of the study was the legislative and by-laws regulating the sphere of circulation of medicines of the Russian Federation and the common market of the EAEU. The search for regulatory legal acts was carried out in the Directory of the legal system “ConsultantPlus”. In the course of the research, a set of scientific methods was used such a systematic, logical, structural and comparative.Results. The article consider the issues of legal regulation of the circulation of medicines “in bulk” in the pharmaceutical market. The current state of the legislative and regulatory framework has been studied and the problems of legal regulation of packaging of medicicnes “in bulk” in pharmacies have been identified. The article also focuses on the general problem of compliance with modern packaging requirements for medicines compounded in pharmacy. The possibility of introducing a new concept of “Pharmacy packaging” into Federal Law No. 61-FZ dated April 12, 2010 “On the circulation of medicines” is considered. The approaches developed in world practice to the regulation of issues related to the packaging of drugs “in bulk” in pharmacy are considered. Based on the results of the study, the possibilities have been identified and ways to improve the mechanisms of state regulation have been proposed.Conclusion. Packaging of medicines “in bulk” will increase the effectiveness of individual drug therapy, optimize and reduce the cost of circulation of budget funds, pharmacies and citizens.
- Open Access
- 29 June 2025
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 12 (5) , 324-337
Regulation in the sphere of circulation of extemporaneously compounded medicines under modern conditions of Russia
The aim of the work was to analyze the current regulatory legal framework governing the manufacture of drugs in pharmacies, and a comprehensive review of the current state of their manufacture; a disclosure of problems and search for the ways to improve the sphere of circulation of extemporaneously compounded medicines (ECMs).Materials and methods. The national legislation of the Russian Federation and the regulatory framework of the medicines common market of the Eurasian Economic Union in the field of an extemporaneous drugs circulation formed a regulatory base of the work. To collect and analyze the information data, the materials presented on the official websites of the Ministry of Health of Russia, the Ministry of Industry and Trade of Russia have been used. The results of the scientific publications for the previous 10 years (2014–2024) have also been analyzed.Results. The article deals with the current state issues of the drug products manufactured in pharmacies, in the sphere of circulation. The analysis of the legislative base on ECMs has been carried out, the problems of the normative legal regulation of the pharmacy drugs manufacturing have been identified. The introduction of new relevant concepts into Federal Law No. 61-FZ “On Circulation of Medicines” — “extemporaneous drug products”, “extemporaneous manufacturing”, “extemporaneous production” — has been proposed. The authors’ definition of the “pharmaceutical sovereignty” concept was given in the course of the study. Based on the results of the study, the possibilities and ways of improving the mechanisms of the state regulation of the drugs extemporaneous manufacturing in the current political and economic conditions have been identified.Conclusion. The operational management and systematization of the regulatory legal framework of the ECMs circulation sphere based on the regulatory science is the most important factor in increasing the affordable, effective, personalized pharmaceutical care. An important element of the mobilization model of the economy is strengthening of the state regulation, development of the domestic production capacities and technologies, including taking into account extemporaneous manufacturing of drugs and small-scale production.
- 29 June 2025
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 12 (5) , 324-337
Open AccessRegulation in the sphere of circulation of extemporaneously compounded medicines under modern conditions of Russia
The aim of the work was to analyze the current regulatory legal framework governing the manufacture of drugs in pharmacies, and a comprehensive review of the current state of their manufacture; a disclosure of problems and search for the ways to improve the sphere of circulation of extemporaneously compounded medicines (ECMs).Materials and methods. The national legislation of the Russian Federation and the regulatory framework of the medicines common market of the Eurasian Economic Union in the field of an extemporaneous drugs circulation formed a regulatory base of the work. To collect and analyze the information data, the materials presented on the official websites of the Ministry of Health of Russia, the Ministry of Industry and Trade of Russia have been used. The results of the scientific publications for the previous 10 years (2014–2024) have also been analyzed.Results. The article deals with the current state issues of the drug products manufactured in pharmacies, in the sphere of circulation. The analysis of the legislative base on ECMs has been carried out, the problems of the normative legal regulation of the pharmacy drugs manufacturing have been identified. The introduction of new relevant concepts into Federal Law No. 61-FZ “On Circulation of Medicines” — “extemporaneous drug products”, “extemporaneous manufacturing”, “extemporaneous production” — has been proposed. The authors’ definition of the “pharmaceutical sovereignty” concept was given in the course of the study. Based on the results of the study, the possibilities and ways of improving the mechanisms of the state regulation of the drugs extemporaneous manufacturing in the current political and economic conditions have been identified.Conclusion. The operational management and systematization of the regulatory legal framework of the ECMs circulation sphere based on the regulatory science is the most important factor in increasing the affordable, effective, personalized pharmaceutical care. An important element of the mobilization model of the economy is strengthening of the state regulation, development of the domestic production capacities and technologies, including taking into account extemporaneous manufacturing of drugs and small-scale production.
- 30 December 2024
- Published by Technomed Holdings LLC in "Medical & Pharmaceutical Journal "Pulse"
ANALYSING THE VOLUME OF DRUG CONSUMPTION IN INPATIENT TREATMENT OF EPILEPSY
The article presents the results of the study of the volume of consumption of medicinal drugs for the treatment of patients diagnosed with epilepsy. As a result of retrospective processing of case histories (continuous sampling for 2021-2023) obtained in the inpatient department of the Clinic of Nervous Diseases named after A.Y. Khlebnikov of Sechenov University, the dynamics of drugs consumption from 2021 to 2023 was analyzed. The range of antiepileptic drugs in the clinic in 2022-2023 compared to 2021 was supplemented with such names as: topiramate, oxcarbazepine. Increased consumption of levetiracetam in 2023 compared to 2021 by 4 times. Based on the data obtained, it is obvious that there are no 3rd generation antiepileptic drugs in the assortment. Among other pharmacotherapeutic groups the leading position is occupied by B vitamins, the volume of consumption of these drugs in 2023 amounted to 496.86 NDDD/100 bed days. In addition, a decrease in the consumption of myorelaxants should be noted. The results obtained can be the basis for the development of recommendations to optimize the use of drugs and improve the quality of drug care for patients with epilepsy at the inpatient level.
- 30 December 2024
- Published by Technomed Holdings LLC in "Medical & Pharmaceutical Journal "Pulse"
ANALYSING THE VOLUME OF DRUG CONSUMPTION IN INPATIENT TREATMENT OF EPILEPSY
The article presents the results of the study of the volume of consumption of medicinal drugs for the treatment of patients diagnosed with epilepsy. As a result of retrospective processing of case histories (continuous sampling for 2021-2023) obtained in the inpatient department of the Clinic of Nervous Diseases named after A.Y. Khlebnikov of Sechenov University, the dynamics of drugs consumption from 2021 to 2023 was analyzed. The range of antiepileptic drugs in the clinic in 2022-2023 compared to 2021 was supplemented with such names as: topiramate, oxcarbazepine. Increased consumption of levetiracetam in 2023 compared to 2021 by 4 times. Based on the data obtained, it is obvious that there are no 3rd generation antiepileptic drugs in the assortment. Among other pharmacotherapeutic groups the leading position is occupied by B vitamins, the volume of consumption of these drugs in 2023 amounted to 496.86 NDDD/100 bed days. In addition, a decrease in the consumption of myorelaxants should be noted. The results obtained can be the basis for the development of recommendations to optimize the use of drugs and improve the quality of drug care for patients with epilepsy at the inpatient level.
- 30 October 2024
- Published by Technomed Holdings LLC in "Medical & Pharmaceutical Journal "Pulse"
ANALYSING THE VOLUME OF DRUG CONSUMPTION IN INPATIENT TREATMENT OF EPILEPSY
The article presents the results of the study of the volume of consumption of medicinal drugs for the treatment of patients diagnosed with epilepsy. As a result of retrospective processing of case histories (continuous sampling for 2021-2023) obtained in the inpatient department of the Clinic of Nervous Diseases named after A.Y. Kozhevnikov of Sechenov University, we identified medicines with the highest NDDD value (number of defined daily doses) for each of the 8 allocated clinical and statistical groups. Among all clinical and statistical groups, the G40.0 group had the highest consumption. In clinical and statistical groups G40.0, G40.8 and G40.9, valproic acid and levetiracetam were found to have the highest NDDD value. In addition, the consumption volume analysis showed that in clinical and statistical group G40.8, the neuroleptics quetiapine and teraligene are used relatively more frequently than in other diagnoses. In clinical and statistical groups G40.1, G40.2, and G40.4, the medicines valproic acid, levetiracetam, and lamotrigine were used, respectively. B vitamins accounted for the highest consumption among all clinical and statistical groups, except for G40.2. The results obtained may become the basis for the development of recommendations to optimize the use of medicines and improve the quality of drug care for patients with epilepsy at the inpatient stage.
- 30 October 2024
- Published by Technomed Holdings LLC in "Medical & Pharmaceutical Journal "Pulse"
ANALYSING THE VOLUME OF DRUG CONSUMPTION IN INPATIENT TREATMENT OF EPILEPSY
The article presents the results of the study of the volume of consumption of medicinal drugs for the treatment of patients diagnosed with epilepsy. As a result of retrospective processing of case histories (continuous sampling for 2021-2023) obtained in the inpatient department of the Clinic of Nervous Diseases named after A.Y. Kozhevnikov of Sechenov University, we identified medicines with the highest NDDD value (number of defined daily doses) for each of the 8 allocated clinical and statistical groups. Among all clinical and statistical groups, the G40.0 group had the highest consumption. In clinical and statistical groups G40.0, G40.8 and G40.9, valproic acid and levetiracetam were found to have the highest NDDD value. In addition, the consumption volume analysis showed that in clinical and statistical group G40.8, the neuroleptics quetiapine and teraligene are used relatively more frequently than in other diagnoses. In clinical and statistical groups G40.1, G40.2, and G40.4, the medicines valproic acid, levetiracetam, and lamotrigine were used, respectively. B vitamins accounted for the highest consumption among all clinical and statistical groups, except for G40.2. The results obtained may become the basis for the development of recommendations to optimize the use of medicines and improve the quality of drug care for patients with epilepsy at the inpatient stage.
- 30 April 2023
- Published by Technomed Holdings LLC in "Medical & Pharmaceutical Journal "Pulse"
ORPHAN DISEASES: REGULATION OF DRUG PROVISION FOR PATIENTS IN RUSSIA
In conditions of budget deficit, the issues of drug provision for patients suffering from life-threatening and chronic progressive rare (orphan) diseases require constant monitoring by regulatory authorities. In this regard, the purpose of the work was to analyze the main aspects of the legal regulation of drug provision for persons with rare (orphan) diseases. The lack of funds in the regions which could fully meet the needs of patients with rare (orphan) diseases in the provision of medicines, served as a weighty argument for the launch of the state federal program for high-costnosologies and the centralization of public procurement of medicines. The key tool for improving drug care was the approval of lists of orphan diseases and the introduction of the federal register of patients eligible for preferential drug provision into the unified information and analytical healthcare system. An important and defining moment of federalization of procurement of medicines was the creation of a federal state institution under the Ministry of Health "Federal Center for Planning and Organization of Drug Provision for Citizens". The main additional mechanism and alternative solution for providing medicines to children under 18 with severe life-threatening and chronic diseases, including rare (orphan) diseases, was the charitable support fund "Circle of Good" created by presidential decree. The financial and organizational approach and the decision of the regulator to federalize the procurement of orphan medicines under the high-cost nosology program makes it possible to increase the equal availability of medicines to persons with rare (orphan) diseases in all subjects of the Russian Federation and to reduce the costs of budget allocations.
- 30 April 2023
- Published by Technomed Holdings LLC in "Medical & Pharmaceutical Journal "Pulse"
ORPHAN DISEASES: REGULATION OF DRUG PROVISION FOR PATIENTS IN RUSSIA
In conditions of budget deficit, the issues of drug provision for patients suffering from life-threatening and chronic progressive rare (orphan) diseases require constant monitoring by regulatory authorities. In this regard, the purpose of the work was to analyze the main aspects of the legal regulation of drug provision for persons with rare (orphan) diseases. The lack of funds in the regions which could fully meet the needs of patients with rare (orphan) diseases in the provision of medicines, served as a weighty argument for the launch of the state federal program for high-costnosologies and the centralization of public procurement of medicines. The key tool for improving drug care was the approval of lists of orphan diseases and the introduction of the federal register of patients eligible for preferential drug provision into the unified information and analytical healthcare system. An important and defining moment of federalization of procurement of medicines was the creation of a federal state institution under the Ministry of Health "Federal Center for Planning and Organization of Drug Provision for Citizens". The main additional mechanism and alternative solution for providing medicines to children under 18 with severe life-threatening and chronic diseases, including rare (orphan) diseases, was the charitable support fund "Circle of Good" created by presidential decree. The financial and organizational approach and the decision of the regulator to federalize the procurement of orphan medicines under the high-cost nosology program makes it possible to increase the equal availability of medicines to persons with rare (orphan) diseases in all subjects of the Russian Federation and to reduce the costs of budget allocations.
- 30 July 2022
- Published by Technomed Holdings LLC in "Medical & Pharmaceutical Journal "Pulse"
MODELING OF THE SELECTION OF MEDICINES IN THE LIST OF VITAL AND ESSENTIAL MEDICINES BY QUALITATIVE INDICATORS
The variety of medicines in circulation on the pharmaceutical market causes the problem of rational choice of medicines for their inclusion in restrictive lists. To form a list of vital and essential medicines (VED), the regulator uses certain rules approved at the legislative level. It should be noted that the determining factor for rational therapy is the evaluation of medicine in terms of the ratio "efficacy / safety". Based on this, the purpose of this study was to develop the process of graphical modeling process when the medicine is included in the VED list in terms of its qualitative characteristics – efficiency and safety. The source was data from Appendix No. 6 "Integral scales of the comprehensive evaluation of a medicinal product" to the " Rules for the formation of lists of medicines for medical use and the minimum range of medicines necessary for the provision of medical care". The developed modeling process eliminates the need to evaluate all indicators in case of obtaining a negative qualifying result in its initial parts, eliminates the need for mathematical operations, and competently ranks the criteria of the selected medicine to the comparison medicine, thus allowing to choose the most preferable option in the case of evaluating several medicines of a single action and significantly speeds up the procedure for a comprehensive assessment of medicine. The model enables the regulator to have a clearer decision-making procedure for the formation of a defining restrictive list of VED in the Russian healthcare system. Thus, the proposed graphical model makes it possible to simplify and, thereby, expedite the process of including medicines in the list of vital and essential medicines of VED.
- 30 July 2022
- Published by Technomed Holdings LLC in "Medical & Pharmaceutical Journal "Pulse"
MODELING OF THE SELECTION OF MEDICINES IN THE LIST OF VITAL AND ESSENTIAL MEDICINES BY QUALITATIVE INDICATORS
The variety of medicines in circulation on the pharmaceutical market causes the problem of rational choice of medicines for their inclusion in restrictive lists. To form a list of vital and essential medicines (VED), the regulator uses certain rules approved at the legislative level. It should be noted that the determining factor for rational therapy is the evaluation of medicine in terms of the ratio "efficacy / safety". Based on this, the purpose of this study was to develop the process of graphical modeling process when the medicine is included in the VED list in terms of its qualitative characteristics – efficiency and safety. The source was data from Appendix No. 6 "Integral scales of the comprehensive evaluation of a medicinal product" to the " Rules for the formation of lists of medicines for medical use and the minimum range of medicines necessary for the provision of medical care". The developed modeling process eliminates the need to evaluate all indicators in case of obtaining a negative qualifying result in its initial parts, eliminates the need for mathematical operations, and competently ranks the criteria of the selected medicine to the comparison medicine, thus allowing to choose the most preferable option in the case of evaluating several medicines of a single action and significantly speeds up the procedure for a comprehensive assessment of medicine. The model enables the regulator to have a clearer decision-making procedure for the formation of a defining restrictive list of VED in the Russian healthcare system. Thus, the proposed graphical model makes it possible to simplify and, thereby, expedite the process of including medicines in the list of vital and essential medicines of VED.